ACXP

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTOThese initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in C. difficile Infection (CDI)As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDASTATEN ISLAND, N.Y., Aug. 17, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or th

STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2026.   Highlights of the second quarter ended June 30, 2026, or in some cases shortly thereafter, include:In April 2026, the Company announced the closing of a registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) priced at-the-m

10-Q - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

STATEN ISLAND, N.Y., Aug. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the Japan Patent Office and the Mexico Patent Office, respectively, have each granted a new patent which covers Acurx's DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent addition to the Company's expanding series of granted patents in the U.S. and abroad. To da

This new partnership builds on the previously reported successful results from the innovative research grant received in November 2025 from Health-Holland to Leiden University and AcurxThis prior work included high-resolution elucidation of the interaction of ibezapolstat with its molecular target, DNA polymerase IIIC (pol IIIC, also known as PolC), with mechanistic findings that explain its properties of lacking cross-resistance with other antibiotics and not fostering the emergence of vancomycin-resistant Enterococcus strains, a unique differentiation among anti-CDI antibioticsThe new research partnership aims to generate the first-ever 3D structure of PolC from methicillin-resistant Staph

Acurx has received FDA guidance in meeting minutes from a July 13, 2026 Type C Meeting to discuss ibezapolstat's (IBZ) Phase 3 clinical program, including the potential to submit an NDA (New Drug Application) based on a single Phase 3 trial and a clinical trial design intended to support indications for both treatment and reduction of recurrence of Clostridioides difficile infection (CDI)FDA stated that it is open to further discussion on the totality of evidence from the clinical development program at a pre-NDA meeting after completion of a single Phase 3 trial and any other clinical trials conducted prior to the pre-NDA meeting, particularly if the clinical efficacy results are robustAddi

Data demonstrated beneficial bacterial taxa persist in fecal samples from patients with rCDI despite multiple prior CDI treatments with the antibiotic standards of care, vancomycin (VAN) and/or fidaxomicin (FDX)Following acute treatment with ibezapolstat (IBZ), these beneficial microorganisms will have the opportunity to repopulate the microbiome in a beneficial way that may prevent recurrenceIBZ and FDX were superior in biofilm experimental models with IBZ significantly more effective at killing C. difficile than VAN and FDXTrial start-up activities for a ground-breaking clinical trial in patients with multiply-recurrent CDI (rCDI) have been initiated with the first patient expected to enro

STATEN ISLAND, N.Y., July 8, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2026 financial results on Friday, August 14, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:               Friday, August 14, 2026  Time:               8:00 a.m. ET    Toll free (U.S.

Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitorsLUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteriaHigh-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2ÅThe Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a devel

424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2026.   Highlights of the first quarter ended March 31, 2026, or in some cases shortly thereafter, include:In February 2026, we announced that the USPTO granted a new patent for our DNA pol IIIC inhibitors covering composition of matter and method of use. This patent extends to December 2039, subject to extension under US patent rules. This adds to our extensi

EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

10-Q - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activityNeutropenic CD-1 mice were infected intramuscularly with methicillin-resistant Staphylococcus aureus (MRSA) and subsequently treated with one of three Acurx DNA pol IIIC inhibitors, linezolid, or placebo administered orallyAcurx compounds achieved potentially therapeutic plasma levels and reduced MRSA tissue burdenAcurx antibiotics maintained a substantially higher gut microbial diversity and a community structure similar to baseline and distinct from linezolidUnlike linezolid, ACX compounds maintain Bacteroidota-dominant community structure and prevent

D - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (NASDAQ:ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections announced today that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase on Wednesday, May 24, 2025. A replay of the presentation will be available under the News / Events tab of the Acurx website following the event at www.acurxpharma.com.About Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of s

4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)